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ABSTRACT
Background: The AIBL study, which commenced in November 2006, is a two-center prospective study of a
cohort of 1112 volunteers aged 60+. The cohort includes 211 patients meeting NINCDS-ADRDA criteria
for Alzheimer’s disease (AD) (180 probable and 31 possible). We aimed to identify factors associated with
rapid cognitive decline over 18 months in this cohort of AD patients.
Methods: We defined rapid cognitive decline as a drop of 6 points or more on the Mini-Mental State
Examination (MMSE) between baseline and 18-month follow-up. Analyses were also conducted with a
threshold of 4, 5, 7 and 8 points, as well as with and without subjects who had died or were too severely
affected to be interviewed at 18 months and after, both including and excluding subjects whose AD diagnosis
was “possible” AD. We sought correlations between rapid cognitive decline and demographic, clinical and
biological variables.
Results: Of the 211 AD patients recruited at baseline, we had available data for 156 (73.9%) patients at 18
months. Fifty-one patients were considered rapid cognitive decliners (32.7%). A higher Clinical Dementia
Rating scale (CDR) and higher CDR “sum of boxes” score at baseline were the major predictors of rapid
cognitive decline in this population. Furthermore, using logistic regression model analysis, patients treated
with a cholinesterase inhibitor (CheI) had a higher risk of being rapid cognitive decliners, as did males and
those of younger age.
Conclusions: Almost one third of patients satisfying established research criteria for AD experienced rapid
cognitive decline. Worse baseline functional and cognitive status and treatment with a CheI were the major
factors associated with rapid cognitive decline over 18 months in this population.
Key words: dementia, cognitive testing, memory, cognitive disorders, cholinesterase inhibitor
Introduction
In Australia the percentage of the total population
with dementia is expected to rise from 1% at
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present to 2.8% by 2050 (Access Economics,
2009). As is the case elsewhere, Alzheimer’s disease
(AD) is the main cause of dementia in Australia.
AD is a progressive disorder, but the rate of
cognitive decline in AD varies considerably between
individuals, with some patients showing rapid and
substantial cognitive decline in a relatively short
time and others showing little or no change
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over years (Doody et al., 2001; Capitani et al.,
2004). Patients with rapid cognitive decline have a
worse prognosis in terms of function and mortality
(O`Hara et al., 2002; Holtzer et al., 2003). A number
of studies (Sona et al., submitted) have tried to
find factors associated with rapid cognitive decline
(usually defined in terms of decline in MMSE
score), because the prior identification of patients
likely to decline quickly could be useful for care
planning and might one day permit the application
of early interventions designed to slow decline or
reduce carer burden.
The Australian Imaging, Biomarkers and
Lifestyle (AIBL) study of aging (Ellis et al.,
2009) is a large longitudinal study designed
to enhance knowledge about AD. It is a two-
center (Melbourne and Perth), prospective study
using neuroimaging, biomarkers, clinical and
neuropsychological measures, and diet and lifestyle
patterns in a cohort of 1112 volunteers comprising
patients with AD or mild cognitive impairment
(MCI; Winblad et al., 2004; Petersen et al., 2009)
and healthy volunteers. AIBL was launched in
November 2006 and comprehensive baseline data
collection and follow-up assessments (18 months
post-baseline) have been completed. It is expected
that 3-year follow-up data will be available for
analysis within 12 months and collection of data
at 54 months will commence during 2011. The
baseline cohort included 211 patients (180 probable
and 31 possible) with AD diagnosed according to
the NINCDS-ADRDA criteria (McKhann et al.,
1984; when the study commenced these were the
most up to date clinical research diagnostic criteria
for AD available). It is this cohort which is the
specific focus of this paper. The aim of this study
was to identify factors associated with, or predictive
of, rapid cognitive decline in these 211 AD patients.
Methods
The population at baseline and methods of the
AIBL study are fully described in an earlier paper
(Ellis et al., 2009). Participants in the AIBL study
were invited to undergo reassessment 18 months
after a baseline assessment. At both time points
data collection included comprehensive cognitive
testing, drawing of 80 ml of blood, and completion
of health and lifestyle questionnaires. One quarter
of the subjects underwent cerebral PET imaging
with Pittsburgh Compound B (PiB) (Rowe et al.,
2010). Assessments took place at three locations in
Melbourne and at two locations in Perth, depending
on whether the participants were to undergo brain
imaging and where they lived. A small number
of participants with advanced AD were assessed
by AIBL staff where they lived. All assessments
were conducted in the mornings, after an overnight
fast. Weight, height, abdominal girth, sitting blood
pressure and pulse were measured, followed by the
drawing of 80 ml of blood. Participants were then
provided with breakfast, followed by cognitive and
mood assessments, including the Mini-Mental State
Examination (MMSE; Folstein et al., 1975). For
a comprehensive account of the cognitive battery
and the rationale behind the selection of individual
items, see our baseline paper (Ellis et al., 2009). On
completion of the 18-month follow-up assessments,
a database of the 211 AD patients was created and
analysis was performed on this subgroup only. For
the definition of rapid cognitive decline we used a
drop of 6 points or more on the MMSE between the
baseline and the 18-month follow-up. The threshold
of 6 points was selected on the basis of the literature,
which suggests a loss of 3 points per year as the mean
rate of decline on the MMSE in patients with AD
(Clark et al., 1999). Analysis was also conducted
with a threshold of 4, 5, 7 and 8 points. Another set
of analyses was conducted on deceased patients (n =
17) and on patients with “AD too severe for follow-
up” (n = 9) as rapid cognitive decliners. Last, we
also conducted analyses excluding the 31 patients
classified as “possible AD” by NINCDS-ADRDA
criteria.
We searched for a correlation between rapid
cognitive decline and those variables which were
collected from participants during their baseline
AIBL visit, and which have been assessed in other
studies of rapid cognitive decline in AD: age, sex,
family history of dementia, level of education,
smoking habits, diabetes, hypertension, angina or
heart attack, cholesterol levels, C-Reactive Protein
(CRP), cerebrovascular disease, ApoE genotype,
brain derived neurotrophic factor (BDNF),
treatment with cholinesterase inhibitors (CheI)
and baseline cognitive function as assessed by the
Clinical Dementia Rating scale (CDR; Morris,
1993) and the MMSE (Folstein et al., 1975) scores
(for a detailed review see Sona et al., submitted).
Statistical analysis
All the analyses used the statistical package “R”
(R Development Core Team, 2010). In all the
analyses “family history”, “smoker”, “smokes more
than one packet a day”, “hypertension”, “angina”,
“heart attack”, “ApoE”, “CheI” were considered
as categorical variables with values “yes” or
“no”. “Education” was categorized as over 12
years or not more than 12 years, and sex has
“female” or “male” values. Other variables –
including “age”, “CDR score”, “CDR sum
of Boxes”, “cholesterol”, “triglycerides”, “HDL
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cholesterol”, “LDL cholesterol”, “BDNF”, “CRP”
and “MMSE” – were treated as continuous
variables, as they were recorded.
In univariate analyses, an odds ratio was
calculated for each categorical variable comparing
the rapid cognitive declining group with the rest.
A 95% confidence level was chosen for calculating
the confidence interval. The comparisons of each
continuous variable between the two groups were
performed with a t-test, and a p value of 0.05
(one tail) was used to define statistical significance.
For multivariate analysis, a multivariate logistic
regression model was constructed based on all
variables mentioned in this study.
Results
Of the 211 AD patients recruited at baseline, we
had available data for 156 (73.9%) patients at
18 months. The reasons why some patients did
not undergo 18-month reassessment are shown in
Figure 1. Characteristics of the AD population at
baseline and follow-up are shown in Table 1. The
mean baseline MMSE for 211 subjects was 19.0
(±5.2) (19.1 ±5.2 at baseline for the 156 patients
with data at both time points), while at 18-month
follow-up it was 15.4 (±7.0) for 156 subjects, with
a mean drop in the score of 3.8 (±4.5) points. The
mean baseline CDR “sum of boxes” for 211 subjects
was 5.7 (±2.9), while at 18-month follow-up for 156
subjects with data it was 8.4 (±4.3) with a mean
gain of 3.0 (±3.0). One-hundred-and-twenty-eight
patients (60.7%) were prescribed a CheI at baseline
and 12 of these patients were taking concomitant
memantine. No patient was prescribed memantine
without a CheI.
Compared to the 156 patients who could be
reassessed after 18 months, patients who did not
return for follow-up (n = 55) were older (mean age
81.7 vs 76.9 years, p = 0.001), had higher baseline
CDR scores (1.2 vs 0.9, p = 0.024) and CDR sum
of boxes scores (6.7 vs 5.4, p = 0.016), and had
slightly lower baseline MMSE scores (18.4 vs 19.2,
p = 0.342). There were no significant differences
in sex ratios or years of education for those who
did and did not return for follow-up, but those who
did not return for follow-up were significantly more
likely not to carry the APOE ε4 allele (26/55 (47%)
APOE ε4 positive vs 106/156 (68%) p = 0.01, one-
tailed). Subjects who could not be reassessed were
less likely to have been taking a CheI at baseline
than those who returned for follow up (25/55 (45%)
taking a CheI vs 103/156 (66%), p = 0.005, one-
tailed).
Table 2 shows the statistically significant
correlations between rapid cognitive decline and
Baseline cohort 
18-month follow-up 
Entered (n = 211 ) 
Lost to follow up (n = 55) 
Reason for not undergoing 
reassessment:
Deceased (n=17) 
AD “too severe” (n=9) 
“Too ill for assessment” (n=10) 
Not contactable (n=7) 
“Found the cognitive assessment 
too hard” (n=5) 
“Too busy” (n=2) 
Involved in “too many” research 
projects (n=2) 
No reason given (n=3) 
Analyzed (n = 156) 
Figure 1. Patient flow
the analyzed factors. Univariate analysis showed
that a higher CDR and CDR “sum of boxes”
scores and use of a CheI were predictors of
rapid cognitive decline in this population. No
significant correlation with rapid cognitive decline
was found for age, family history of dementia,
level of education, presence of any cardiovascular
risk factor (smoking habits, diabetes, hypertension,
angina or heart attack, cholesterol levels, CRP),
cerebrovascular disease, ApoE genotype or BDNF.
In the multivariate analysis (logistic regression
model) younger age, male sex and CheI treatment
made a significant contribution to distinguishing the
rapid cognitive decliners from the slow decliners.
The multivariate logistic regression model in
this study was used to give the adjusted odds
ratios corresponding to the variables in univariate
analysis. It simply included all the variables used
for the univariate analysis without investigation
of interactions between the variables or any
variable selection. The odds ratio results from
the model showed that there might be some
confounding or high correlations between some
variables. We investigated the correlations between
the variables. CDR score and CDR sum of
Boxes are highly correlated as expected (Spearman
correlation coefficient 0.8). Total cholesterol is also
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Table 1. Characteristics of the sample (baseline and 18-month follow-up)
BASELINE FOLLOW-U P
CHARACTERI S T I C M E A N(±SD) OR NUMBER(%) MEAN(±SD) OR NUMBER(%)
...................................................................................................................................................................................................................................................................................................
AD patients 211 (100%) 156 (73.9%)
Age 78.1 (±8.6) 76.9 (±8.1)
Female 130 (61.6%) 96 (61.5%)
ApoE ε4+ 132 (62.6%) 106 (67.9)
Years of education (≤12 years) 121 (59.1%) 85 (55.5%)
MMSE 19.0 (±5.2) 15.4 (±7.0)
CDR 1.0 (±0.5) 1.4 (±0.8)
CDR Sum of Boxes 5.7 (±2.9) 8.4 (±4.3)
Rapid cognitive decliners (loss – 51 (32.7%)
of 6 MMSE points or more)
SD = Standard Deviation; AD = Alzheimer’s disease; MMSE = Mini-Mental State Examination; CDR = Clinical Dementia
Rating scale; CheI = cholinesterase inhibitor.
Table 2. Predictors of rapid cognitive decline (statistically significant results in italics)
M U LT I VA R I AT E A NA LY SI S (L O G I S T I C
R E GRESSION) UNIVARIAT E A NALY SIS
CATEGORICAL LR
VARIABLES COEFFICIENT OR 95% CI P VALUES O R 95% CI
.........................................................................................................................................................................................................................................................................................................................
Family history of 0.7 2.0 0.8 5.4 0.16 1.7 0.8 3.5
dementia
Smoking 0.1 1.2 0.4 3.4 0.79 1.1 0.5 2.4
Smokes ≥1 packet of 1.9 6.9 1.1 49.5 0.04 2.4 0.6 9.7
cigarettes
Stroke or TIA 1.1 2.9 0.8 10.9 0.11 1.8 0.7 4.4
Diabetes 0.1 1.1 0.2 5.7 0.92 0.9 0.3 2.6
Hypertension −0.4 0.7 0.2 1.9 0.45 0.8 0.4 1.7
Angina 0.4 1.6 0.3 8.8 0.62 0.8 0.2 2.6
Heart attack 0.8 2.2 0.3 17.5 0.46 1.1 0.2 4.2
ApoE ε4 −0.1 0.9 0.3 3.0 0.90 1.2 0.6 2.8
Education (>12 years) 0.2 1.2 0.4 3.5 0.73 0.9 0.4 1.9
CheI 1.5 4.3 1.3 17.6 0.03 3.4 1.5 8.9
Gender (male) −1.3 0.3 0.1 0.9 0.05 0.6 0.3 1.3
.........................................................................................................................................................................................................................................................................................................................
CONTINUOUS
VARIABLES RCD Mean SCDMean P values
.........................................................................................................................................................................................................................................................................................................................
Age −0.1 0.9 0.9 1.0 0.05 76.7 77.0 0.9
CDR score 1.4 4.2 0.4 48.3 0.23 1.1 0.9 0.0
CDR sum of boxes 0.1 1.1 0.7 1.7 0.73 6.3 5.1 0.0
Total cholesterol 2.8 16.3 0.0 >1000 0.76 5.3 5.5 0.4
Triglycerides −1.1 0.3 0.0 >1000 0.80 1.3 1.4 0.5
HDL cholesterol −2.7 0.1 0.0 >1000 0.77 1.7 1.7 0.5
LDL cholesterol −3.1 0.0 0.0 >1000 0.74 3.0 3.1 0.3
BDNF −0.1 0.9 0.8 1.1 0.53 1.8 1.8 0.9
CRP −0.1 0.9 0.8 1.0 0.37 2.3 3.3 0.3
MMSE −0.02 1.0 0.8 1.1 0.75 18.0 19.6 0.1
LR = logistic regression; OR = odds ratio; CI = confidence interval; TIA = transient ischemic attack; AD = Alzheimer’s disease. CheI,
Cholinesterase Inhibitor. MMSE, Mini-Mental State Examination. CDR = Clinical Dementia Rating scale. CheI = choleinesterase
inhibitors; BDNF = brain derived neurotrophic factor; CRP = C-reactive Protein; RCD = rapid cognitive decliners; SCD = slow
cognitive decliners.
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highly correlated with LDL cholesterol (Pearson
correlation coefficient 0.9).
Analysis with a threshold of 4, 5, 7 or 8
MMSE points to define rapid decline showed no
trend towards significance for any other variables
but confirmed the same correlations with baseline
functional and cognitive status and CheI treatment.
Analysis was also carried out on the deceased
patients (n = 17) and the patients whose AD was
“too severe” (n = 9) as rapid cognitive decliners
and this statistical analysis showed no significant
difference from previous ones regarding factors
associated with rapid cognitive decline. Excluding
the 31 “possible AD” subjects from the analyses
did not affect any of the results.
Discussion
The first issue raised by this work is the definition
of rapid cognitive decline (for a detailed review of
this subject see Sona et al., submitted). A recent
consensus paper (Soto et al., 2008a) sought to
establish a definition of rapid cognitive decline,
with the authors proposing “the loss of 3 points
or greater in MMSE during six months” . In their
paper the authors noted that only a few studies had
tried to define rapid cognitive decline: in an earlier
paper, Soto et al. (2005) proposed a 4 point or
greater loss on the MMSE within 6 months and
the loss of at least 1 more point on the MMSE
during the following six months; Carcaillon et al.
(2007), in their bid to find a significant threshold
of decline associated with a higher mortality rate,
proposed a loss of 3 points or greater per year
on the MMSE; Soto et al. (2008b) concluded that
the loss of 4 points or more in the MMSE during
the first 6 months of follow-up was a predictor of
a worse clinical course of AD. Two later papers
give a definition of rapid cognitive decline based
on the MMSE: Doody et al. (2010) who used
the same definition as in a previous study (Doody
et al., 2001), dividing patients into slow progressors
(decline of less than 2 points per year on the
MMSE), intermediate progressors (2 to 4 points
per year) and rapid progressors (≥5 points per
year); and Musicco et al. (2010) who considered
the time-dependent probability of losing 5 points
on the MMSE over two years as rapid disease
progression. The rationale behind our choice of the
loss of 6 points or more over 18 months is based
on the fact that cognitive decline is not linear, as
is demonstrated by recent research (Mendiondo
et al., 2000). Also, the literature suggests a loss
of some 3 points per year as the mean rate of
decline on the MMSE in AD (Clark et al., 1999),
so 6 points lost in 18 months clearly would be
faster than the average rate of decline. We were
constrained in our assessments of decline by the
fact that funding only permits reassessment of
the AIBL cohort every 18 months. Most of the
studies noted above gave a definition of rapid
cognitive decline based on the rate of decline
of their particular population, but this procedure
could enhance intrinsic variation among the studied
subjects. We chose to give a reasonable (even if
partly empirical) definition of rapid decline which
is independent of our population characteristics and
easily reproducible. Furthermore, we repeated our
analyses using different MMSE decline thresholds,
without and with patients who died and those
whose symptoms were too severe for follow-up, and
both including and excluding NINCDS-ADRDA
possible AD patients, and no significant change in
our results was found.
The main findings of this study are: (1) nearly
a third of patients satisfying strict clinical criteria
for AD are likely to experience a rapid cognitive
decline; (2) worse baseline cognitive function and
greater functional impairment are correlated with
rapid cognitive decline; and (3) treatment with a
CheI at baseline is also associated with a higher risk
of rapid cognitive decline.
Using a definition of rapid cognitive decline as a
drop of 6 points on the MMSE, almost one third
of the patients had declined to this extent after 18
months. This figure is consistent with other reports:
for example, Atchison et al. (2004) and Carcallion
et al. (2007) reported 33.6% and 33.9% of patients
respectively who were rapid cognitive decliners.
This subgroup of patients may need a higher level
of attention than their counterparts. As they are
declining rapidly, one could argue that they should
be the target of specific measures to delay their
cognitive deterioration. Unfortunately, the lack of
clearly defined characteristics associated with rapid
cognitive decline (Sona et al., submitted) makes
the early recognition of these patients extremely
difficult, and to date there is a lack of effective
disease modifying strategies available for AD.
The finding of an association between initial
cognitive and functional status (as defined by
the CDR scale) and subsequent decline is not
surprising, as many studies demonstrate that
patients who are more severely impaired in the
early stages are more likely to decline faster than
less impaired patients (Morris et al., 1993; Doody
et al., 2001; Bhargava et al., 2006; Ousset et al.,
2008). But the literature also contains some
contradictory results: Burns et al. (1991) found
that cognitive function at baseline was associated
with accelerated decline only for patients at an
intermediate level of impairment at baseline; and a
very recent paper published in this journal (Brodaty
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et al., 2011) demonstrated in a large sample of
patients (n = 967) attending several different
memory clinics in Australia that higher baseline
MMSE scores (better cognition) were associated
with faster cognitive decline over a period of 6
months. The authors pointed out that 6 months is
a relatively short period of time to detect predictors
of disease progression and that a floor effect could
not be ruled out as an influencing factor, since
the most impaired patients (those at the low end
of MMSE score) had less room to decline over
the 6-month period. Different recruitment settings
(memory clinics versus volunteers) could go some
way towards explaining these differences, as those
who volunteer for research studies are likely to form
a selected subsample of those with AD diagnosed via
memory clinics. Furthermore, these results appear
to be consistent with the course of decline in MMSE
scores from early to severe stages of AD: subjects
with intermediate stages of disease tend to have
a greater decline in cognitive function than those
with mild or severe impairment. Graphically, the
course of cognitive decline assessed by the MMSE
scale would look like a sinusoid, suggesting that the
scale is more sensitive to changes in the middle to
late stages of AD (Mendiondo et al., 2000). Also,
cognitive tests may not be sensitive to all stages of
the disease, especially for patients with the least and
the greatest impairments (Flicker, 2010).
Our finding of a higher risk of being a rapid
cognitive decliner when treated with a CheI
was surprising to us, given the internationally
recognized beneficial effect of CheIs in the mild to
moderate stages of AD, which has been documented
in numerous prospective randomized controlled
trials (Birks, 2006). In addition, at least one other
study found that the use of CheIs for at least
one year was associated with a decreased risk of
rapid cognitive deterioration (Gillette-Guyonnet
et al., 2006). However, our surprise was attenuated
when we read the recent paper of Schneider
et al. (2011), which reports more rapid decline
in people with both MCI and AD in the ADNI
cohort who were prescribed either a CheI or
memantine (we were unable to analyze the effect
of memantine on our cohort as only 12 subjects
took it at baseline and all were taking a concomitant
ChEI). As has been suggested in relation to MCI
subjects by Schneider et al., perhaps clinicians
treating AD participants in the AIBL study are
selecting individuals with more aggressive disease
progression for drug therapy, while adopting a more
conservative approach to those with slower disease
progression. We doubt that differential dropout of
slowly progressing patients produced this result, as
our dropouts tended to be more impaired at baseline
than those we were able to reassess. However,
significantly fewer dropouts were prescribed a CheI
at baseline than were the 156 subjects who were
reassessed, and this may mean that some rapidly
declining subjects who were not on a CheI were
missed at follow-up, potentially inflating the effect
of CheI prescription on the result for those who
were reassessed, though it is notable that including
the cases who had died or whose AD was too
severe for reassessment in the analysis did not
affect the significance of the association with CheI
prescription and rapid decline. Of course, it is
possible that the finding with respect to baseline
CheI prescription occurred by chance, and our
results should not be interpreted as a reason to deny
established palliative treatment to people affected
by AD. We will be interested to see whether any
future AD cohort studies replicate or contradict this
result. Our paper relates only to subjects with AD,
but future analysis of other AIBL data is unlikely
to cast further light on the relationship of CheI
prescribing with rapid decline in MCI, as such
treatment is rarely used by Australian clinicians
for subjects diagnoses with MCI and fewer than
10 AIBL MCI subjects were taking any cognitive
enhancer at baseline.
Some limitations need to be acknowledged
when reviewing our data. First of all, the number
of patients is relatively small (even if very well
characterized) and may not represent a sufficiently
large sample from which to generalize our results.
Second, the outcome choice of a drop of 6
points on the MMSE in 18 months is reasonable,
but not universally accepted as a way to define
rapid cognitive decline. Last, this study is based
on a convenience sample of AD subjects who
volunteered to take part in prospective research
and they may not be representative of the wider
population of people with AD.
More research is needed to better identify AD
patients who are at higher risk of rapid cognitive
decline in order prospectively to assess the effect
of interventions (pharmacological and/or social) in
delaying progression or reducing costs and to ensure
that the best available level of care is provided to
such patients.
Conflict of interest declaration
D. Ames is former Editor-in-Chief of International
Psychogeriatrics. He has received payment for
advisory board participation and support to attend
conferences from companies marketing cognitive
enhancing agents.
N. Lautenschlager is the Editor-in-Chief of
International Psychogeriatrics. She has received
payment for advisory board membership and
Rapid cognitive decline in AD: a prospective study 203
support to attend conferences from companies
marketing cognitive enhancing agents.
This paper was peer-reviewed independently
through the office of one of the deputy editors.
Description of authors’ roles
A. Sona assembled the data for analysis, assisted
with the analysis and wrote drafts of the paper while
he was a visiting fellow at NARI from September
2010 to April 2011. P. Zhang designed and executed
the statistical analyses and wrote sections of the
paper. D. Ames and K. Ellis oversaw the AIBL study
in all its aspects, conceived the research question,
supervised A. Sona and reviewed and revised
successive drafts of the paper. N. Lautenschlager
assisted with development of the research question,
supervision of the study, confirmation of diagnoses
and writing of the paper. A. Bush, R. Martins, C.
Masters, C. Rowe and C. Szoeke oversaw the AIBL
study and contributed to drafts of the paper. K.
Taddei managed AIBL data collection in Perth and
contributed to drafts of the paper.
Acknowledgments
Core funding for the study was provided
by CSIRO, which was supplemented by “in
kind” contributions from the study partners
(Australian Commonwealth Scientific Industrial
and Research Organization (CSIRO), University of
Melbourne, Neurosciences Australia Ltd. (NSA),
Edith Cowan University (ECU), Mental Health
Research institute (MHRI), Alzheimer’s Australia
(AA), National Ageing Research Institute (NARI),
Austin Health, University of WA (UWA), CogState
Ltd., Macquarie University, Hollywood Private
Hospital, and Sir Charles Gairdner Hospital).
The AIBL investigators thank Richard Head of
CSIRO for initiating and facilitating the AIBL
collaboration. The study also received support
from the National Health and Medical Research
Council (NHMRC) via the Dementia Collaborative
Research Centres program (DCRC2). Pfizer
International has contributed financial support
to assist with analysis of blood samples and to
further the AIBL research program. Cassandra
Szoeke has been partially supported by research
fellowships funded by Alzheimer’s Australia and
the NHMRC. Alzheimer’s Australia (Victoria and
Western Australia) assisted with promotion of
the study and the screening of telephone calls
from volunteers. The AIBL team wishes to thank
the clinicians who referred patients with AD
to the study: Professor David Ames, Associate
Professor Brian Chambers, Professor Edmond
Chiu, Dr Roger Clarnette, Associate Professor
David Darby, Dr Mary Davison, Dr John Drago,
Dr Peter Drysdale, Dr Jacqueline Gilbert, Dr
Kwang Lim, Professor Nicola Lautenschlager, Dr
Dina LoGiudice, Dr Peter McCardle, Dr Steve
McFarlane, Dr Alastair Mander, Dr John Merory,
Professor Daniel O’Connor, Professor Christopher
Rowe, Dr Ron Scholes, Dr Mathew Samuel, Dr
Darshan Trivedi, and Associate Professor Michael
Woodward. We thank all those who participated in
the study for their commitment and dedication to
helping advance research into the early detection
and causation of AD.
References
Access Economics (2009). Keeping Dementia Front of Mind:
Incidence and Prevalence 2009–2050. Canberra: Alzheimer’s
Australia.
Atchison, T. B., Bradshaw, M. and Massman, P. J.
(2007). Investigation of profile difference between
Alzheimer’s disease patients declining at different rates:
examination of baseline neuropsychological data. Archives
of Clinical Neuropsychology, 19, 1007–1015.
Birks, J. (2006). Cholinesterase inhibitors for Alzheimer’s
disease. Cochrane Database of Systematic Reviews, 1,
CD005593.
Bhargava, D., Weiner, M. F., Hynan, L. S.,
Diaz-Arrastia, R. and Lipton, A. M. (2006). Vascular
disease and risk factors, rate of progression, and survival in
Alzheimer’s disease. Journal of Geriatric Psychiatry and
Neurology, 19, 78–82.
Brodaty, H., Woodward, M., Boundy, K., Ames, D. and
Balshaw, R. (2011). Patients in Australian memory
clinics: baseline characteristics and predictors of decline at
6 months. International Psychogeriatrics. Epublished ahead
of print, doi:10.107/S1041610211000688.
Burns, A., Jacoby, R. and Levy, R. (1991). Progression of
cognitive impairment in Alzheimer’s disease. Journal of the
American Geriatrics Society, 39, 39–45.
Capitani, E., Cazzaniga, R., Francescani, A. and
Spinnler, H. (2004). Cognitive deterioration in
Alzheimer’s disease: is the early course predictive of the
later stages? Neurological Sciences, 25, 198–204.
Carcallion, L., Peres, K, Pere, J. J., Helmer, C.,
Orgogozo, J. M., Dartigues, J. F. (2007). Fast cognitive
decline at the time of dementia diagnosis: a major
prognostic factor for survival in the community. Dementia
and Geriatric Cognitive Disorders, 24, 138–145.
Clark, C. M. et al. (1999). Variability in annual Mini-Mental
State Examination score in patients with probable
Alzheimer disease. Archives of Neurology, 56, 857–
862.
Doody, R. S., Massman, P. and Dunn, K. (2001). A
method for estimating progression rates in Alzheimer’s
disease. Archives of Neurology, 58, 449–454.
Doody, R. S., Pavlik, V., Massman, P., Rountree, S.,
Darby, E. and Chan, W. (2010). Predicting progression
204 A. Sona et al.
of Alzheimer’s disease. Alzheimer’s Research and Therapy, 2,
2–9.
Ellis, K. A., et al. (2009). The Australian Imaging,
Biomarkers and Lifestyle (AIBL) study of aging:
methodology and baseline characteristics of 1112
individuals recruited for a longitudinal study of Alzheimer’s
disease. International Psychogeriatrics, 21, 672–687.
Flicker, L. (2010). Screening and assessment instruments for
the detection and measurement of cognitive impairment. In
D. Ames, A. Burns, A. and J. O’Brien (eds.), Dementia 4th
edn. (p. 57). London: Hodder Arnold.
Folstein, M. F., Folstein, S. E. and McHugh, P. R. (1975).
“Mini-mental state”: a practical method for grading the
cognitive state of patients for the clinician. Journal of
Psychiatric Research, 12, 189–198.
Gillette-Guyonnette, S., et al. (2006). Outcome of
Alzheimer’s disease: potential impact of cholinesterase
inhibitors. Journals of Gerontology, Series A: Biological
Sciences and Medical Sciences, 61, 516–520.
Holtzer, R. et al. (2003). The rate of cognitive decline and
risk of reaching clinical milestones in Alzheimer’s disease.
Archives of Neurology, 60, 1137–1142.
McKhann, G., Drachman, D., Folstein, M., Katzman,
R., Price, D. and Stadlan, E. M. (1984). Clinical
diagnosis of Alzheimer’s disease: report of the
NINCDS-ADRDA Work Group under the auspices of the
Department of Health and Human Services Task Force on
Alzheimer’s disease. Neurology, 34, 939–944.
Mendiondo, M. S., Ashford, J. W., Kryscio, R. J. and
Schmitt, F. A. (2000) Modeling Mini Mental State
Examination changes in Alzheimer’s disease. Statistical
Medicine, 19, 1607–1616.
Morris, J. C. (1993). The Clinical Dementia Rating (CDR):
current version and scoring rules. Neurology, 43,
2412–2414.
Morris, J. C., et al. (1993). The consortium to establish a
registry for Alzheimer’s disease (CERAD). Part IV. Rates of
cognitive change in the longitudinal assessment of probable
Alzheimer’s disease. Neurology, 43, 2457–2465.
Musicco, M. et al. (2010). Neuropsychological predictors of
rapidly progressing patients with Alzheimer’s disease.
Dementia and Geriatric Cognitive Disorders, 30, 219–
228
O’Hara, R. et al. (2002). Which Alzheimer patients are at
risk for rapid cognitive decline? Journal of Geriatric
Psychiatry and Neurology, 15, 233–238.
Ousset, P. J., Nourhashemi, F., Reynish, E. and Vellas,
B. (2008). Nutritional status is associated with disease
progression in very mild Alzheimer disease. Alzheimer
Disease and Associated Disorders, 22, 66–71.
Petersen, R. C. et al. (2009). Mild cognitive impairment: ten
years later. Archives of Neurology, 66, 1447–1455.
R Development Core Team (2010). R: a Language and
Environment for Statistical Computing. Vienna: R Foundation
for Statistical Computing. See http://www.R-project.org.
Rowe, C. et al. (2010). Amyloid imaging results from the
Australian Imaging, Biomarkers and Lifestyle (AIBL) study
of aging. Neurobiology of Aging, 31, 1275–1283.
Schneider, L. S., Insel, P. S. and Weiner, M. W. for the
Alzheimer’s Disease Neuroimaging Initiative. (2011).
Treatment with cholinesterase inhibitors and memantine of
patients in the Alzheimer’s Disease Neuroimaging
Initiative. Archives of Neurology, 68, 58–66.
Sona, A., Ellis, K. and Ames, D. (submitted). Rapid
cognitive decline in Alzheimer’s disease: a selective review
of the literature. Submitted to International Psychogeriatrics.
Soto, M. E., Gillette-Guyonnet, S., Vellas, B. and the
REAL.FR group. (2005). Rapid cognitive decline:
searching for a definition and predictive factor among
elderly with Alzheimer’s disease. Journal of Nutrition, Health
and Aging, 9, 158–161.
Soto, M. E. et al. (2008a). Rapid cognitive decline in
Alzheimer disease. Consensus paper Journal of Nutrition
Health and Aging, 12, 703–713.
Soto, M. E. et al. (2008b). Predictive value of rapid decline in
Mini Mental State Examination in clinical practice for
prognosis in Alzheimer’s disease. Dementia and Geriatric
Cognitive Disorders, 26, 109–116.
Winblad, B. et al. (2004). Mild cognitive impairment –
beyond controversies, towards a consensus: report of the
International Working Group on Mild Cognitive
Impairment. Journal of Internal Medicine, 256, 240–246.
